IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 1, 2013, Pages 9-16

  Zeremski, Marija ^a   Dimova, Rositsa B ^a   Makeyeva, Jessy ^a   Sipley, John D ^b   Jacobson, Ira M ^a   Rennert, Hanna ^a   Talal, Andrew H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

CXCL10; hepatitis C virus treatment; IL28B; predictors of treatment outcome; treatment biomarkers

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIVIRAL AGENTS; CHEMOKINE CXCL10; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84876298587     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828323c1     Document Type: Article

References (28)

1. World Health Organization. Hepatitis C. Fact sheet No. 164. 2011. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed October 12, 2011.
2. Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090-1101.
3. Brown RS. Hepatitis C and liver transplantation. Nature. 2005;436: 973-978.
4. Kadam JS, Talal AH. Changing treatment paradigms: hepatitis C virus in HIV-infected patients. AIDS Patient Care STDS. 2007;21:154-168.
5. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: 975-982.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: 958-965.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
9. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
10. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
11. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014-1024.
12. Butera D, Marukian S, Iwamaye AE, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood. 2005;106:1175-1182.
13. Lagging M, Romero AI, Westin J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44:1617-1625.
14. Zeremski M, Markatou M, Brown QB, et al. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr. 2007;45:262-268.
15. Payer BA, Reiberger T, Aberle J, et al. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest. 2012;42:599-606.
16. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
17. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-1104.
18. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.
19. Rallon NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23-F29.
20. Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology. 2011;53:14-22.
21. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798-801.
22. Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One. 2011;6:e17232.
23. Fattovich G, Covolo L, Bibert S, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther. 2011;33:1162-1172.
24. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372-374.
25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
26. Diago M, Castellano G, Garcia-Samaniego J, et al. Association of pretreat-ment serum interferon {gamma} inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut. 2006;55:374-379.
27. Apolinario A, Diago M, Lo Iacono O, et al. Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. Aliment Pharmacol Ther. 2004;19:551-562.
28. Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis. 2006;194:895-903.